MCK -- Fiscal Q1 2027 earnings preview

The setup is constructive, but the hurdle is more nuanced than a simple revenue beat. The Street expects $103.88 billion of revenue and $9.56 of adjusted EPS, equal to 6.2% and 15.7% year-over-year growth, respectively. That combination already assumes McKesson converts a mid-single-digit top-line result into mid-teens EPS growth. The clean positive outcome is therefore an EPS beat supported by segment operating profit, stable prescription utilization, and continued specialty and oncology momentum -- not merely higher pass-through drug revenue.

Our base case is $103.6 billion of revenue and $9.60 of adjusted EPS. The revenue estimate applies the midpoint of management's segment growth ranges to the prior-year quarter; it is a transparent run-rate estimate, not a substitute for the unavailable internal analyst model. We expect management to reaffirm the $43.80-$44.60 FY2027 adjusted EPS range. A modest raise would be a positive surprise this early in the year, while a reaffirmation with stronger operating profit language would still be sufficient.

The most important debate is whether the mix shift is working. North American Pharmaceutical revenue can be noisy because of GLP-1 volumes, branded drug pricing, Rite Aid comparisons, and customer onboarding. Oncology & Multispecialty and Prescription Technology Solutions carry better fundamental signal. Sustained double-digit oncology operating-profit growth, continued demand for access solutions, and progress on Medical-Surgical separation would support the long-term 13%-16% EPS algorithm.

| Metric | Q1 FY2026 actual | Q1 FY2027 Street | Internal base | What clears the bar | |---|---:|---:|---:|---| | Revenue | $97.83B | $103.88B | $103.6B | At least 6% growth with healthy segment profit | | Adjusted EPS | $8.26 | $9.56 | $9.60 | Beat with operating support, not a discrete tax benefit | | Adjusted operating profit | $1.42B | Not publicly available | $1.55B-$1.60B | High-single/low-double-digit growth | | FY2027 adjusted EPS | $39.11 FY2026 base | Not publicly available | $43.80-$44.60 guide | Reaffirm; a raise is upside | | FY2027 free cash flow | $5.41B FY2026 actual | Not publicly available | $4.5B-$4.9B guide | No deterioration in working-capital commentary |

Public sources do not provide a reliable fiscal Q2 or FY2028 consensus set. Those fields are intentionally left unmodeled rather than inferred. The first-quarter Street estimates above are third-party consensus snapshots as of July 30.

| Metric | FY2027 company guide | Internal view | Preview judgment | |---|---:|---:|---| | Revenue growth | 5%-9% | 6%-8% | Mid-range is achievable despite price and customer noise | | Adjusted operating profit growth | 8%-12% | 9%-11% | Mix and efficiency should do the work | | Adjusted EPS | $43.80-$44.60 | $44.20-$44.60 | Upper half is achievable if buybacks track plan | | Free cash flow | $4.5B-$4.9B | $4.7B-$4.9B | Timing explains part of the FY2026 step-down | | Share repurchases | Approximately $5.0B | Approximately $5.0B | Medical-Surgical proceeds increase visibility | | Diluted shares | 116M-118M | 116M-118M | A major part of the EPS growth bridge |

Management said the FY2027 EPS cadence should be broadly similar to fiscal 2026 between the first and second halves. It also noted that the guide represents 14%-16% underlying growth after excluding the prior-year Norway contribution and a $51 million investment gain. That makes Q1's expected 15.7% EPS growth consistent with the underlying algorithm, even though it sits above the 12%-14% reported full-year guide.

| Segment | Q1 FY2026 revenue | FY2027 company growth guide | Internal Q1 view | Key proof point | |---|---:|---:|---:|---| | North American Pharmaceutical | $82.73B | 4%-8% revenue; 5.5%-9.5% profit | $86.9B | Specialty growth and stable utilization offset branded-price pressure | | Oncology & Multispecialty | $10.66B | 14.5%-18.5% revenue; 13.5%-17.5% profit | $12.4B | Organic growth remains near 13% as PRISM/Core anniversary | | Prescription Technology Solutions | $1.43B | 2.5%-6.5% revenue; 11%-15% profit | $1.50B | Access-solutions profit outgrows lumpy 3PL revenue | | Medical-Surgical Solutions | $2.70B | 1%-6% revenue; 0%-4% profit | $2.80B | Separation costs and execution stay controlled |

The internal segment build sums to approximately $103.6 billion, close to the Street. The more differentiated call is on operating profit: Oncology and RxTS should remain the strongest contributors, while North American Pharmaceutical should demonstrate that branded-price declines and GLP-1 variability do not impair economics.

| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 Street | |---|---:|---:|---:|---:|---:| | Revenue | $97.83B | $103.15B | $106.16B | $96.30B | $103.88B | | Revenue growth | 23.4% | 10.1% | 11.4% | 6.0% | 6.2% | | Adjusted EPS | $8.26 | $9.86 | $9.34 | $11.69 | $9.56 | | Adjusted EPS growth | 4.8% | 39.5% | 16.3% | 15.5% | 15.7% | | Adjusted operating profit | $1.42B | $1.63B | $1.65B | $1.76B | Not publicly available |

Revenue growth decelerated through the year as acquisition timing, customer onboarding, branded-price changes, and Rite Aid distorted comparisons. The better signal was operating profit: it rose 13% in Q4 while revenue rose 6%. Q1 needs to preserve that operating leverage.

Eight-quarter trend

| Fiscal quarter | Revenue | Revenue YoY | Adjusted EPS | Adjusted EPS YoY | Adjusted operating profit | Profit YoY | |---|---:|---:|---:|---:|---:|---:| | Q1 FY2025 | $79.28B | -- | $7.88 | -- | $1.31B | -- | | Q2 FY2025 | $93.65B | -- | $7.07 | -- | $1.29B | -- | | Q3 FY2025 | $95.29B | -- | $8.03 | -- | $1.46B | -- | | Q4 FY2025 | $90.82B | -- | $10.12 | -- | $1.56B | -- | | Q1 FY2026 | $97.83B | 23.4% | $8.26 | 4.8% | $1.42B | 9.1% | | Q2 FY2026 | $103.15B | 10.1% | $9.86 | 39.5% | $1.63B | 26.4% | | Q3 FY2026 | $106.16B | 11.4% | $9.34 | 16.3% | $1.65B | 12.9% | | Q4 FY2026 | $96.30B | 6.0% | $11.69 | 15.5% | $1.76B | 12.7% |

YoY growth is shown only where the dashboard's source set contains the matching prior-year quarter. The trajectory says top-line growth normalized sharply, while operating-profit growth remained double digit in the second half. That divergence supports management's argument that revenue is an imperfect economic signal for a pharmaceutical distributor.

Five-year annual trend

| Fiscal year | Revenue | Revenue growth | Adjusted EPS | Adjusted EPS growth | |---|---:|---:|---:|---:| | FY2022 | $263.97B | -- | $23.69 | -- | | FY2023 | $276.71B | 4.8% | $25.94 | 9.5% | | FY2024 | $308.95B | 11.6% | $27.44 | 5.8% | | FY2025 | $359.05B | 16.2% | $33.05 | 20.4% | | FY2026 | $403.43B | 12.4% | $39.11 | 18.3% |

Over five years, adjusted EPS compounded faster than revenue as operating leverage and share repurchases augmented the scaled distribution model. Revenue growth decelerated 380 basis points in FY2026, but adjusted EPS growth slowed only 210 basis points and remained above the long-term 13%-16% target.

Management's differentiated claim is that lower reported revenue growth does not mean weaker economics. It argues that branded-price declines, GLP-1 variability, Rite Aid, and customer timing affect revenue more than operating profit, while specialty distribution, Oncology, RxTS access solutions, efficiency, and repurchases support durable EPS growth. The Street hurdle captures some of this with 15.7% expected Q1 EPS growth against 6.2% revenue growth. The remaining debate is whether double-digit operating-profit growth can persist as acquisition comparisons normalize. That is the most important thesis test on August 5.

| Quarter | Consensus EPS | Actual adjusted EPS | Surprise | Read | |---|---:|---:|---:|---| | Q4 FY2026 | $11.56 | $11.69 | +1.1% | Small beat; revenue quality remained debated | | Q3 FY2026 | $9.17 | $9.34 | +1.9% | Beat and FY2026 guide raise | | Q2 FY2026 | $9.03 | $9.86 | +9.2% | Material upside | | Q1 FY2026 | $8.14 | $8.26 | +1.5% | Beat and guide raise | | Q4 FY2025 | $9.83 | $10.12 | +3.0% | Beat |

McKesson has beaten the published EPS forecast in five consecutive quarters. The median surprise is roughly 1.9%, so a merely in-line quarter would feel softer than the recent pattern. Historical forecast and actual values are from the TipRanks earnings history.

1. North American Pharmaceutical economics. Q4 GLP-1 distribution revenue rose 22% year over year but fell 4% sequentially, while branded price declines reduced segment revenue growth by about three points. Management said neither affected operating profit. Q1 should confirm that claim.
2. Oncology organic durability. The segment grew Q4 revenue 35%, helped by PRISM Vision and Core Ventures. As those deals anniversary, organic growth near management's cited 13% rate becomes the cleaner test.
3. RxTS profit versus revenue. Approximately 55% of segment revenue comes from lumpy 3PL activity. Access and affordability programs -- including GLP-1 support -- should keep operating-profit growth well above revenue growth.
4. Medical-Surgical separation. Apollo's $1.25 billion investment closed June 1 for an approximately 13% interest, valuing the business at roughly $13 billion enterprise value. Watch the IPO timetable, stranded costs, incremental debt, and noncontrolling-interest accounting.
5. Cash conversion. FY2027 free-cash-flow guidance is below the $5.41 billion FY2026 result. Management attributes much of the difference to unusually favorable prior-year working-capital timing. Q1 commentary should support that explanation.

| Date | Development | Preview implication | |---|---|---| | Jun. 2, 2026 | Apollo minority investment in Medical-Surgical closed | Financing milestone lowers separation risk; Q1 should clarify remaining steps | | Jun. 24, 2026 | August 5 earnings date confirmed | Results after close; call at 4:30 p.m. ET | | Q1 FY2027 | PRISM and Core Ventures reach first anniversary | Reported oncology growth should transition toward organic growth | | FY2027 | Approximately $5B planned repurchases | Share-count delivery is central to the EPS bridge | | FY2027 | Planned Medical-Surgical IPO | Separation execution and stranded-cost control remain catalysts |

• CFO transition: Britt Vitalone retired after the fiscal Q4 call. The team should listen for continuity in guidance discipline and capital allocation.
• Revenue-quality optics: High drug-price pass-through can move revenue without changing profit; a revenue beat with weak segment profit is low quality.
• Policy and pricing: Inflation Reduction Act price changes, biosimilar adoption, and branded manufacturer price declines can distort reported growth.
• Customer and credit exposure: Prior-year comparisons include a large customer onboarding and Rite Aid revenue. The Q1 FY2026 Rite Aid bankruptcy also caused a $189 million GAAP bad-debt provision.
• Separation complexity: Medical-Surgical remains consolidated, while debt, preferred equity, noncontrolling interest, and transition costs complicate the earnings bridge.
• FCF conversion: A further reduction below the $4.5B-$4.9B guide would challenge the working-capital-timing explanation.

1. How much of Oncology & Multispecialty growth is organic now that PRISM Vision and Core Ventures are anniversarying, and is organic growth still near 13%?
2. Did GLP-1 distribution volumes reaccelerate from Q4's sequential decline, and do manufacturer price changes remain neutral to operating profit?
3. What portion of RxTS growth came from technology-enabled access solutions versus 3PL, and is the 11%-15% operating-profit guide tracking as planned?
4. What milestones remain before the Medical-Surgical IPO, and how should investors model stranded costs and noncontrolling interest through separation?
5. How much of Q1 free cash flow reflects calendar timing, and does the company still expect $4.5B-$4.9B for the year?
6. Is first-half/second-half EPS cadence still expected to resemble fiscal 2026, and were there any discrete tax benefits in Q1?
7. Does the $43.80-$44.60 EPS guide still assume approximately $5B of repurchases and 116M-118M diluted shares?

| Scenario | Revenue / EPS | Guidance | Fundamental interpretation | |---|---|---|---| | Bull | Revenue at or above $104B; EPS at or above $9.75 | EPS range raised or upper-half confidence | Oncology/RxTS profit and buybacks more than offset top-line noise | | Base | Revenue $102.5B-$104B; EPS $9.45-$9.75 | Reaffirmed | Operating algorithm intact; focus shifts to Q2 and separation milestones | | Bear | Revenue below $102.5B; EPS below $9.45 | Range or FCF tone softens | Mix, pricing, working capital, or separation costs are pressuring conversion |